Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain.
Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain.
复制标题
低剂量纳洛酮对神经性角膜疼痛患者的症状调节有效且耐受性良好。
DOI：
10.1016/j.jtos.2020.12.003
复制
发表时间：
2021-04
期刊：
影响因子：
6.4
通讯作者：
Hamrah, Pedram
中科院分区：
文献类型：
--
作者：
Dieckmann, Gabriela;Ozmen, M. Cuneyt;Cox, Stephanie M.;Engert, Ryan C.;Hamrah, Pedram
Neuropathic corneal pain (NCP) is caused by damage or disease of the somatosensory nervous system that innervates the cornea and presents with symptoms of pain or persistent unpleasant sensations, such as burning, dryness, or light sensitivity. This retrospective study aims to assess the efficacy and tolerability of low-dose naltrexone (LDN) in refractory NCP patients. Fifty-nine NCP patients with a centralized component treated with oral LDN 4.5 mg at bedtime for at least four weeks were identified. Thirty out of 59 patients who had a baseline pain score ≥4 on the visual analogue scale had completed the ocular pain assessment survey (OPAS) and presented persistent pain, despite instillation of topical anesthetic drops, were included. Changes in pain scores, comorbidities, side effects, among others, were analyzed. Change in ocular pain scores (scale 0–10) and quality of life (QoL) scores (scale 0–100%) were the main endpoints. Mean age (years ± SD) was 45.60 ± 19.30 with a white (80.00%) female (73.33%) predominance. Duration of LDN use was 14.87 ± 11.25 months, and the duration of NCP before treatment was 17.53 ± 17.29 months. Eight patients used LDN as a monotherapy, whereas the remaining used it as an adjunct therapy. LDN resulted in a 49.22% decrease in mean pain score from 6.13 ± 1.93 to 3.23 ± 2.60 (p < 0.001). Mean QoL scores by the OPAS were 5.84 ± 2.57 at the first visit and improved to 3.77 ± 2.91 at the last visit (p = 0.023). Common side effects were vivid dreams, headaches, and stomachache. LDN was effective and well-tolerated for NCP treatment.
登录
查看更多内容
影响因子：
13.7
作者：
Qazi Y;Hurwitz S;Khan S;Jurkunas UV;Dana R;Hamrah P
通讯作者：
Hamrah P
影响因子：
15.9
作者：
Lutz PE;Kieffer BL
通讯作者：
Kieffer BL
DOI：
10.1016/j.jtos.2015.01.005
发表时间：
2015-07
期刊：
The ocular surface
影响因子：
--
作者：
Aggarwal S;Kheirkhah A;Cavalcanti BM;Cruzat A;Colon C;Brown E;Borsook D;Prüss H;Hamrah P
通讯作者：
Hamrah P
影响因子：
13.7
作者：
Dieckmann G;Goyal S;Hamrah P
通讯作者：
Hamrah P
影响因子：
4.3
作者：
Kobayashi S
通讯作者：
Kobayashi S